A federal appeals court ruled in favor of the drug, whose authorization was suspended last week. A panel of three judges based in New Orleans decided by two votes to one to uphold the authorization of mifepristone (RU 486) Access will now require three visits to the doctor during the prescription period, which will be limited to the first seven weeks of pregnancy, compared to ten previously.
White House spokeswoman Karine Jean-Pierre said Thursday that the executive branch intends to "continue to fight in court"